Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view
- 31 October 2007
- journal article
- review article
- Published by Elsevier BV in Nuclear Medicine and Biology
- Vol. 34 (7), 757-778
- https://doi.org/10.1016/j.nucmedbio.2007.04.001
Abstract
No abstract availableKeywords
This publication has 155 references indexed in Scilit:
- Editorial: What Ails Solid Tumor Radioimmunotherapy?Cancer Biotherapy & Radiopharmaceuticals, 2006
- Technology Insight: monoclonal antibody imaging of prostate cancerNature Reviews Endocrinology, 2006
- Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generatorNuclear Medicine and Biology, 2005
- Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant GliomasJournal of Clinical Oncology, 2002
- A Prospective Study of 2-[18F] Fluoro-2-Deoxy-D-Glucose/Positron Emission Tomography Scan, 99mTc-Labeled Arcitumomab (CEA-Scan), and Blind Second-Look Laparotomy for Detecting Colon Cancer Recurrence in Patients With Increasing Carcinoembryonic Antigen LevelsAnnals of Surgical Oncology, 2001
- Pre-Targeted Locoregional Radioimmunotherapy with 90Y-biotin in Glioma Patients: Phase I Study and Preliminary Therapeutic ResultsCancer Biotherapy & Radiopharmaceuticals, 2001
- Radiation Absorbed Dose Estimation for 90Y-DOTA-biotin with Pretargeted NR-LU-10/StreptavidinCancer Biotherapy & Radiopharmaceuticals, 1999
- Quantitative and qualitative effects of experimental radioimmunotherapy on tumor vascular permeabilityInternational Journal of Cancer, 1995
- Phase I studies of treatment of malignant gliomas and neoplastic meningitis with131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab?)2-a preliminary reportJournal of Neuro-Oncology, 1995
- Tumor dosimetry in radioimmunotherapy: Methods of calculation for beta particlesMedical Physics, 1993